Paul Tudor Jones Pliant Therapeutics, Inc. Transaction History
Tudor Investment Corp Et Al
- $15.5 Billion
- Q1 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 26,897 shares of PLRX stock, worth $289,142. This represents 0.0% of its overall portfolio holdings.
Number of Shares
26,897Holding current value
$289,142% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding PLRX
# of Institutions
148Shares Held
63.8MCall Options Held
417KPut Options Held
123K-
Deep Track Capital, LP Greenwich, CT5.75MShares$61.8 Million2.83% of portfolio
-
Black Rock Inc. New York, NY4.66MShares$50 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.96MShares$42.6 Million0.01% of portfolio
-
First Light Asset Management, LLC Edina, MN3.53MShares$38 Million4.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.48MShares$37.4 Million0.0% of portfolio
About PLIANT THERAPEUTICS, INC.
- Ticker PLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,682,000
- Market Cap $523M
- Description
- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...